Addressing health disparities in the Food and Drug Administration’s artificial intelligence and machine learning regulatory framework

Previous
Previous

Considering biased data as informative artifacts in AI-assisted health care

Next
Next

Race, genomics and chronic disease: What patients with African ancestry have to say